Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Debt to Equity (2020 - 2025)

Candel Therapeutics' Debt to Equity history spans 4 years, with the latest figure at $1.61 for Q4 2023.

  • On a quarterly basis, Debt to Equity rose 280.36% to $1.61 in Q4 2023 year-over-year; TTM through Dec 2023 was $1.61, a 280.36% increase, with the full-year FY2023 number at $1.61, up 280.36% from a year prior.
  • Debt to Equity hit $1.61 in Q4 2023 for Candel Therapeutics, up from $0.89 in the prior quarter.
  • Over the last five years, Debt to Equity for CADL hit a ceiling of $1.61 in Q4 2023 and a floor of -$0.02 in Q4 2020.
  • Historically, Debt to Equity has averaged $0.45 across 4 years, with a median of $0.4 in 2022.
  • The widest YoY moves for Debt to Equity: up 6479.07% in 2023, down 129.99% in 2023.
  • Tracing CADL's Debt to Equity over 4 years: stood at -$0.02 in 2020, then surged by 144.43% to $0.01 in 2021, then surged by 4749.19% to $0.42 in 2022, then surged by 280.36% to $1.61 in 2023.
  • Business Quant data shows Debt to Equity for CADL at $1.61 in Q4 2023, $0.89 in Q3 2023, and $0.66 in Q2 2023.